Hellebrigenin

Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak) . Hellebrigenin can also induce DNA double-strand breaks to activate the ATM pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers[1][2].

Product Specifications

CAS Number

[465-90-7]

UNSPSC

12352005

Target

Apoptosis; Caspase; ERK; IAP; JNK; p38 MAPK; PARP

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hellebrigenin.html

Purity

99.69

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C[C@@]12[C@]3([H])[C@](CC[C@@]1(C[C@@H](O)CC2)O)([H])[C@@]4([C@@](C)([C@@H](C(C=C5)=COC5=O)CC4)CC3)O

Molecular Formula

C24H32O6

Molecular Weight

416.51

References & Citations

[1]Hsieh MJ, et al. Hellebrigenin induces oral cancer cell apoptosis by modulating MAPK signalling and XIAP expression. J Cell Mol Med. 2024 Jan;28 (2) :e18071.|[2]Deng LJ, et al. Hellebrigenin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells through inhibition of Akt. Chem Biol Interact. 2014 Aug 5;219:184-94.